Proactive Investors ‘ReNeuron focus on new clinical trials’
Proactive investors ‘Breakthrough to open up potential new revenue opportunities for Reneuron Plc’
Shares Investor Evening (Manchester) – October 2018
Proactive Investors : ‘All systems go’ with ReNeuron Group Plc looking to treat first PISCES III patient shortly
CFO fireside chat at ARM Cell & Gene Investor Day
Proactive Investors: Michael Hunt updates on product development
To view the full article click here.
Proactive Investors: ‘Lots to look forward to’ as ReNeuron gets go-ahead for phase IIb stroke trial
Michael Hunt, CFO of ReNeuron Group Plc (LON:RENE), tells Proactive they’ve been given the green light from US authorities to kick off a phase IIb study of its CTX cell therapy candidate for stroke disability.
Long-term data from the PISCES II trial earlier this year showed the treatment has the potential to improve the disability of stroke patients.
PISCES III – as this next study will be called – will be much bigger, recruiting 110 patients across 25 sites in the US.
The approval caps off a productive six months for the cell-based therapeutics specialist, during which it also started dosing patients in the phase II element of the ongoing phase I/II clinical trial of its hRPC stem cell therapy candidate for retinitis pigmentosa
Proactive Investors: Michael Hunt discusses very encouraging long-term stroke data
To view the full article click here…
Proactive Investors: ReNeuron gears up for Phase III stroke disability study
To view the full article click here…
Proactive Investors: ReNeuron ‘greatly encouraged’ by US regulator feedback on CTX cell therapy trial
To view the full article click here…